Table 1 Clinical characteristics of patients with histone H3 K27-mutant diffuse non-midline glioma (n = 16) and H3 G34-mutant diffuse hemispheric glioma (n = 9) in the Kansai Network
Characteristic | H3 K27-mutant diffuse non-midline glioma (n = 16) | H3 G34-mutant diffuse hemispheric glioma (n = 9) | p value |
|---|---|---|---|
Age (y)†| 45 (26–79) | 25 (11–45) | 0.002* |
Sex | 0.8345 | ||
 Female | 6 (37.5%) | 3 (33.3%) |  |
 Male | 10 (62.5%) | 6 (66.7%) |  |
Location | 0.0351* | ||
 Frontal | 4 (25.0%) | 1 (11.1%) |  |
 Front-temporal | 1 (6.3%) | 0 (–) |  |
 Front-parietal | 1 (6.3%) | 0 (–) |  |
 Temporal | 5 (31.3%) | 2 (22.2%) |  |
 Parietal | 1 (6.2%) | 6 (66.7%) |  |
 Basal ganglia | 3 (18.8%) | 0 (–) |  |
 Multiple | 1 (6.3%) | 0 (–) |  |
Preoperative KPS score | 0.7894 | ||
 80–100 | 8 (50%) | 5 (55.6%) |  |
 − 70 | 8 (50%) | 4 (44.4%) |  |
Extent of surgical resection | 0.3222 | ||
 GTR | 2 (12.5%) | 3 (33.3%) |  |
 STR | 2 (12.5%) | 0 (–) |  |
 PR | 4 (25.0%) | 3 (33.3%) |  |
 Biopsy | 8 (50%) | 3 (33.3%) |  |
BCNU wafer | 0.2488 | ||
 Yes | 1 (6.3%) | 2 (22.2%) |  |
 No | 15 (93.8%) | 7 (77.8%) |  |
Adjuvant treatment | 0.5749 | ||
 RT + TMZ | 13 (81.3%) | 8 (88.9%) |  |
 RT alone | 1 (6.3%) | 0 (–) |  |
 TMZ alone | 1 (6.3%) | 0 (–) |  |
 None | 1 (6.3%) | 1 (11.1%) |  |
BEV therapy | 0.9148 | ||
 Yes | 5 (31.3%) | 3 (33.3%) |  |
 No | 11 (68.8%) | 6 (66.7%) |  |
 OS (mo)†| 20 | 22.5 | 0.2958 |